Search PubMedSearch

PubMed · 40950445

Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies.

Elsa Leitão·Amandine Santini·Benjamin Cogne·Myriam Essid·Maria Athanasiadou·Christy W LaFlamme·Pierre Marijon·Virginie Bernard·Nicolas Chatron·Giulia Barcia·Boris Keren·Cyril Mignot·Perrine Charles·Thomas Besnard·Jean-Madeleine de Sainte Agathe·Edith P Almanza Fuerte·Soham Sengupta·Mathieu Milh·Francis Ramond·Talia Allan·Isabelle An·Camila Araujo·Stephanie Arpin·Christina Austin-Tse·Stéphane Auvin·Sarah Baer·Nadia Bahi-Buisson·Mads Bak·Magalie Barth·Stéphanie Baulac·Nathalie Bednark Weirauch·Matthias Begemann·Mark F Bennett·Uriel Bensabath·Stéphane Bézieau·Rakia Bhouri·Margaux Biehler·Trine Bjørg Hammer·Julie Bogoin·Emilie Bonanno·Simon Boussion·Nuria C Bramswig·Céline Bris·Adelaide Brosseau-Beauvir·Ange-Line Bruel·Julien Buratti·Pascal Chambon·Nicole Chemaly·Bertrand Chesneau·Estelle Colin·Maxime Colmard·Solène Conrad·Thomas Courtin·Louis T Dang·Anne de Saint Martin·Caroline de Vanssay de Blavous Legendre·Anne-Sophie Denommé-Pichon·Stephanie DiTroia·Martine Doco-Fenzy·Christèle Dubourg·Charlotte Dubucs·Stéphanie Ducreux·Louis Dufour·Romain Duquet·Benjamin Durand·Salima El Chehadeh·Miriam Elbracht·Laurence Faivre·Marie Faoucher·Anne Faudet·Sylvie Forlani·Mélanie Fradin·Pauline Gaignard·Benjamin Ganne·Aurore Garde·Justine Géraud·Deepak Gill·Alice Goldenberg·David Grabli·Coraline Grisel·Sophie Gueden·Paul Gueguen·Anne-Marie Guerrot·Agnès Guichet·Nina Härting·Martin Georg Häusler·Solveig Heide·Bénédicte Héron·Delphine Héron·Mathilde Heulin·Clara Houdayer·Bertrand Isidor·Aurélia Jacquette·Louis Januel·Nolwenn Jean-Marçais·Kevin Jousselin·Frank J Kaiser·Sabine Kaya·Chontelle King·Marina Konyukh

Abstract

Variants in spliceosomal small nuclear RNA (snRNA) genes RNU4-2 (ReNU syndrome), RNU5B-1, and RNU2-2 have recently been linked to dominant neurodevelopmental disorders (NDDs), revealing a major, previously overlooked role for noncoding snRNAs in human disease. Here, we systematically analysed 200 potentially functional snRNA genes in a French cohort comprising 26,911 individuals with rare disorders and through international collaborations. We identify de novo and biallelic variants in RNU2-2 associated with both dominant and recessive NDDs in 126 individuals from 108 unrelated families. Recessive RNU2-2 NDD is at least twice as frequent as the dominant NDD caused by n.4G>A and n.35A>G, and often arises from a de novo variant in trans with an inherited allele, reflecting the high mutability of snRNA genes. Dominant and recessive RNU2-2-NDDs share overlapping clinical features with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our findings support a gradient-of-impact model and a continuum between dominant and recessive inheritance, establishing RNU2-2 variants as a frequent cause of NDDs, nearly as prevalent as ReNU syndrome.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Elsa Leitão, Amandine Santini, Benjamin Cogne, Myriam Essid, Maria Athanasiadou, Christy W LaFlamme, Pierre Marijon, Virginie Bernard, Nicolas Chatron, Giulia Barcia, Boris Keren, Cyril Mignot, Perrine Charles, Thomas Besnard, Jean-Madeleine de Sainte Agathe, Edith P Almanza Fuerte, Soham Sengupta, Mathieu Milh, Francis Ramond, Talia Allan, Isabelle An, Camila Araujo, Stephanie Arpin, Christina Austin-Tse, Stéphane Auvin, Sarah Baer, Nadia Bahi-Buisson, Mads Bak, Magalie Barth, Stéphanie Baulac, Nathalie Bednark Weirauch, Matthias Begemann, Mark F Bennett, Uriel Bensabath, Stéphane Bézieau, Rakia Bhouri, Margaux Biehler, Trine Bjørg Hammer, Julie Bogoin, Emilie Bonanno, Simon Boussion, Nuria C Bramswig, Céline Bris, Adelaide Brosseau-Beauvir, Ange-Line Bruel, Julien Buratti, Pascal Chambon, Nicole Chemaly, Bertrand Chesneau, Estelle Colin, Maxime Colmard, Solène Conrad, Thomas Courtin, Louis T Dang, Anne de Saint Martin, Caroline de Vanssay de Blavous Legendre, Anne-Sophie Denommé-Pichon, Stephanie DiTroia, Martine Doco-Fenzy, Christèle Dubourg, Charlotte Dubucs, Stéphanie Ducreux, Louis Dufour, Romain Duquet, Benjamin Durand, Salima El Chehadeh, Miriam Elbracht, Laurence Faivre, Marie Faoucher, Anne Faudet, Sylvie Forlani, Mélanie Fradin, Pauline Gaignard, Benjamin Ganne, Aurore Garde, Justine Géraud, Deepak Gill, Alice Goldenberg, David Grabli, Coraline Grisel, Sophie Gueden, Paul Gueguen, Anne-Marie Guerrot, Agnès Guichet, Nina Härting, Martin Georg Häusler, Solveig Heide, Bénédicte Héron, Delphine Héron, Mathilde Heulin, Clara Houdayer, Bertrand Isidor, Aurélia Jacquette, Louis Januel, Nolwenn Jean-Marçais, Kevin Jousselin, Frank J Kaiser, Sabine Kaya, Chontelle King, Marina Konyukh. 2025-09-04. Systematic analysis of snRNA genes reveals frequent RNU2-2 variants in dominant and recessive developmental and epileptic encephalopathies.. https://doi.org/10.1101/2025.09.02.25334923

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article